Clopidogrel added to aspirin adds no benefit but bleeding risk in patients with recent lacunar stroke

Stroke

Volumn 44, Issue 3, 2013, Pages 861-863

  Diener, Hans Christoph ^a   Weber, Ralph ^a,b  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b ALFRIED KRUPP KRANKENHAUS   (Germany)

Author keywords

Aspirin; Clopidogrel; Lacunar stroke; Randomized trial; Stroke prevention

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL;

ARTICLE; BRAIN HEMORRHAGE; CARDIOVASCULAR RISK; HUMAN; LACUNAR STROKE; MORTALITY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE;

ASPIRIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; RISK ASSESSMENT; RISK FACTORS; STROKE, LACUNAR; TICLOPIDINE;

EID: 84876295389     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.112.680751     Document Type: Article

References (17)

1. Adams RJ, Albers G, Alberts MJ, Benavente O, Furie K, Goldstein LB, et al.; American Heart Association; American Stroke Association. Update to the AHA/ASA recommendations for the prevention of stroke in patients with stroke and transient ischemic attack. Stroke. 2008;39: 1647-1652.
2. Furie KL, Kasner SE, Adams RJ, Albers GW, Bush RL, Fagan SC, et al.; American Heart Association Stroke Council, Council on Cardiovascular Nursing, Council on Clinical Cardiology, and Interdisciplinary Council on Quality of Care and Outcomes Research. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/ American Stroke Association. Stroke. 2011;42:227-276.
3. European Stroke Organisation (ESO) Executive Committee and ESO Writing Committee. Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. Cerebrovasc Dis. 2008;25:457-507.
4. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK; Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345:494-502.
5. Connolly SJ, Pogue J, Hart RG, Hohnloser SH, Pfeffer M, Chrolavicius S, et al. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med. 2009;360:2066-2078.
6. Geeganage C, Wilcox R, Bath PM. Triple antiplatelet therapy for preventing vascular events: a systematic review and meta-analysis. BMC Med. 2010;8:36.
7. Diener HC, Weber R, Weimar C, Röther J. Secondary prevention in the acute and early chronic phase after ischaemic stroke and transient ischaemic attacks with antiplatelet drugs-is antiplatelet monotherapy still reasonable? Int J Clin Pract. 2011;65:531-535.
8. Diener H, Bogousslavsky J, Brass L, Cimminiello C, Csiba L, Kaste M, et al. Acetylsalicylic acid on a background of clopidogrel in high-risk patients randomised after recent ischaemic stroke or transient ischaemic attack: The MATCH trial results. Lancet. 2004;364:331-334.
9. Benavente OR, White CL, Pearce L, Pergola P, Roldan A, Benavente MF, et al.; SPS3 Investigators. The Secondary Prevention of Small Subcortical Strokes (SPS3) study. Int J Stroke. 2011;6:164-175.
10. SPS3 Investigators, Benavente OR, Hart RG, McClure LA, Szychowski JM, Coffey CS, et al. Effects of clopidogrel added to aspirin in patients with recent lacunar stroke. N Engl J Med. 2012;367:817-825.
11. Bhatt DL, Fox KA, Hacke W, Berger PB, Black HR, Boden WE, et al.; CHARISMA Investigators. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006;354:1706-1717.
12. Usman MH, Notaro LA, Nagarakanti R, Brahin E, Dessain S, Gracely E, et al. Combination antiplatelet therapy for secondary stroke prevention: enhanced efficacy or double trouble? Am J Cardiol. 2009;103:1107-1112.
13. Sacco RL, Diener HC, Yusuf S, Cotton D, Ounpuu S, Lawton WA, et al.; PRoFESS Study Group. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med. 2008;359: 1238-1251.
14. Morrow DA, Braunwald E, Bonaca MP, Ameriso SF, Dalby AJ, Fish MP, et al.; TRA 2P-TIMI 50 Steering Committee and Investigators. Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med. 2012;366:1404-1413.
15. Scirica BM, Bonaca MP, Braunwald E, De Ferrari GM, Isaza D, Lewis BS, et al.; TRA 2P-TIMI 50 Steering Committee Investigators. Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2P-TIMI 50 trial. Lancet. 2012;380:1317-1324.
16. Chimowitz MI, Lynn MJ, Derdeyn CP, Turan TN, Fiorella D, Lane BF, et al.; SAMMPRIS Trial Investigators. Stenting versus aggressive medical therapy for intracranial arterial stenosis. N Engl J Med. 2011;365:993-1003.
17. Wong KS, Chen C, Fu J, Chang HM, Suwanwela NC, Huang YN, et al.; CLAIR study Investigators. Clopidogrel plus aspirin versus aspirin alone for reducing embolisation in patients with acute symptomatic cerebral or carotid artery stenosis (CLAIR study): a randomised, open-label, blinded-endpoint trial. Lancet Neurol. 2010;9:489-497.